Work Here?
Overview
Blue Industries provides health diagnostics and genetic analysis for individuals and corporate clients, using genetic data to predict health risks and COVID-19 severity risk. It analyzes genetic information with bioinformatics and material science to power online diagnostic platforms delivered via service fees. The company differentiates itself by prioritizing data security, regulatory compliance, and an online-first delivery model for both personal and business customers. Its goal is to offer practical, actionable health insights while protecting personal data and meeting legal standards.
About Blue Industries
Industries
Data & Analytics
Cybersecurity
Biotechnology
Healthcare
Company Size
N/A
Company Stage
Late Stage VC
Total Funding
$950K
Headquarters
Tokyo, Japan
Founded
2015
Get referred to Blue Industries
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 2026 GeneQuest deal expands Blue's cross-sell base and data moat.
- GeneQuest's 2014 service history brings established demand and credibility to Blue.
- Blue now controls a broader preventive-care pathway from genetic insight to screening behavior.
What critics are saying
- Bluedrop remains a risk indicator, not diagnosis, limiting clinician adoption through 2027.
- GeneQuest integration concentrates sensitive genomic data, raising breach and compliance exposure immediately.
- If regulators challenge predictive cancer claims, Blue's consumer diagnostics story collapses quickly.
What makes Blue Industries unique
- August 1, 2026 acquisition of GeneQuest adds 360-trait genetic testing depth.
- Bluedrop links urine miRNA cancer risk screening with inherited-risk genetics in one funnel.
- Blue Industries combines AI, bioinformatics, and consumer diagnostics across home and corporate channels.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$950k
Below
Industry Average
Funded Over
4 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Company News
Blue Industries has acquired all shares of GeneQuest, making it a wholly owned subsidiary effective 1 August 2026. The acquisition was completed through a purchase from Euglena Company. Blue Industries develops Bluedrop, a home-use cancer risk assessment kit that analyses microRNA patterns in urine to evaluate risks for seven types of cancer. GeneQuest has provided genetic testing services since 2014, offering analysis of over 360 hereditary traits including disease risks and physical characteristics. The acquisition aims to create an integrated healthcare pathway combining GeneQuest's genetic analysis with Blue Industries' current cancer risk assessment technology. This will enable users to understand both their inherited disease predispositions and current cancer risks, supporting appropriate screening and medical consultation. GeneQuest's existing management team, led by CEO Osamu Iwata, will continue, with Blue Industries' representatives joining the board. GeneQuest's headquarters will relocate to Blue Industries' office in Tokyo's Chuo ward.
Blue Industries is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Blue Industries
Industries
Data & Analytics
Cybersecurity
Biotechnology
Healthcare
Company Size
N/A
Company Stage
Late Stage VC
Total Funding
$950K
Headquarters
Tokyo, Japan
Founded
2015
Blue Industries is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today